VERTEX PHARMACEUTICALS INC / MA

VRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000875320

Price chart

Open-market purchases and sales by VRTX insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Jul 7, 20264:15 PM ETJul 2, 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.SSaleCommon Stock−1.5K$524.99−$787.49K45.32K−3.2%SEC10b5-1
Jul 7, 20264:08 PM ETJul 2, 2026McKechnie DuncanEVP, Chief Commercial OfficerSSaleCommon Stock−1.54K$519.00−$799.78K11K−12.3%SEC10b5-1
Jul 6, 20264:13 PM ETJul 1, 2026Liu JoyEVP and Chief Legal OfficerSSaleCommon Stock−828$502.71−$416.24K19.13K−4.1%SEC10b5-1
Jun 30, 2026Jun 26, 2026Bozic CarmenEVP and CMOSSaleCommon Stock−596$482.50−$287.57K15.34K−3.7%SEC10b5-1
Jun 23, 2026Jun 18, 2026Bozic CarmenEVP and CMOSSaleCommon Stock−1.02K$462.17−$471.41K15.93K−6.0%SEC10b5-1

The largest institutional positions in VRTX at the end of Q2 2026.

Institutions holding VRTX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Capital World Investors26,115,014$12.97B1.53%+746,890+2.9%Added
BlackRock, Inc.24,109,373$11.98B0.18%+139,856+0.6%Added
Capital Research Global Investors19,490,637$9.68B1.35%−1,635,327−7.7%Reduced
VANGUARD CAPITAL MANAGEMENT LLC16,580,713$8.24B0.18%+67,903+0.4%Added
STATE STREET CORP11,871,459$5.9B0.17%+141,320+1.2%Added